SCHEMBL3904285

SCHEMBL3904285

CC(C)(C)OC(=O)N[C@@H]1CC[C@H](Cc2ccccc2)C1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
KDM1A O60341 1/20 0.55
MAOB P27338 1/20 0.55
DRD2 P14416 8/20 0.55
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA7 P43166 1/20 0.49
CA14 Q9ULX7 1/20 0.49
BTK Q06187 1/20 0.49
EPHX2 P34913 1/20 0.46
KCNA3 P22001 1/20 0.46
DRD3 P35462 1/20 0.45
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21089801 1.00 KMT2A (0.59) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL7467219 0.92 KMT2A (0.58) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL16449452 0.88 DRD2 (0.59) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL19715107 0.84 KMT2A (0.56) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL14069934 0.83 KMT2A (0.53) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL21854002 0.83 KMT2A (0.55) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL19715172 0.83 KMT2A (0.55) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL6642481 0.83 KMT2A (0.52) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL6642475 0.83 KMT2A (0.52) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL3904869 0.82 DRD2 (0.50) KMT2AL3MBTL1KDM1AMAOBDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538128-B2 Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them GLENMARK PHARMACEUTICALS S.A. (CH) 2009-05-26 US disclosed
US-7524844-B2 Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them GLENMARK PHARMACEUTICALS S.A. (CH) 2009-04-28 US disclosed
US-20070238728-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2007-10-11 US disclosed
US-20070232608-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2007-10-04 US disclosed
US-7205323-B2 Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation GLENMARK PHARMACEUTICALS S.A. (CH) 2007-04-17 US disclosed
US-20060142585-A1 Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation GLENMARK PHARMACETUCALS, S.A. 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142585-A1 Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation DPP4, DPP3, DPP7 KMT2A 3383/4885L3MBTL1 4421/4885KDM1A 1380/4885
US-20070232608-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM DPP4, DPP3, DPP7 KMT2A 3071/4885L3MBTL1 3722/4885KDM1A 1023/4885
US-20070238728-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM DPP4, DPP3, DPP7 KMT2A 3071/4885L3MBTL1 3722/4885KDM1A 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.